Navigation Links
Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
Date:5/3/2012

MONTREAL, May 3, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant has agreed to acquire certain assets from University Medical Pharmaceuticals Corp., a specialty pharmaceutical company focused on skincare products, for approximately $64 million plus potential milestones based upon attainment of future revenue targets.  University Medical's main brand is AcneFree, a leading retail over-the-counter (OTC) acne treatment. 

Total revenue in 2011 from the acquired assets was approximately $32 million. The transaction is expected to close by mid-year, subject to certain closing conditions including expiration of requisite regulatory waiting periods, and is expected to be immediately accretive.

"The addition of a leading OTC acne treatment will provide us with the ability to expand our OTC business," stated J. Michael Pearson, chairman and chief executive officer.  "We believe that we can build upon our success with CeraVe in the retail channel through increased offerings to consumers.  These new products will be immediately accretive to our operations and have not been factored into our 2012 financial guidance."

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Caution Regarding Forward-Looking Information
To the extent any statements made in this document contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, "forward-looking statements").

These forward-looking statements relate to, among other things, the closing of the acquisition of certain assets of University Medical by Valeant, the impact of such assets on Valeant's consumer dermatology portfolio, and the expected timing of the acquisition to be accretive.  Forward-looking statements can generally be identified by the use of words such as "believe", "anticipate", "expect", "estimate", "intend", "continue", "plan", "project", "will", "may", "should", "could", "would", "target", "potential" and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.  Actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things, the closing of the acquisition of certain assets of University Medical by Valeant, the impact of such assets on Valeant's consumer dermatology portfolio, and the expected timing of the acquisition to be accretive, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators ("CSA"). 

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals to Announce 2012 First Quarter Results on May 3, 2012
2. Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results
3. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
4. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
5. Valeant Pharmaceuticals Acquires Probiotica in Brazil
6. Valeant Pharmaceuticals Increases Proposed Price for Acquisition of ISTA Pharmaceuticals Inc. to $7.50 Per Share in Cash
7. Fleming Pharmaceuticals Sells Ocean, Nephrocaps, Other Branded Products to Valeant
8. Valeant Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
9. Valeant Pharmaceuticals Completes Acquisition of iNova
10. Valeant Pharmaceuticals to Hold Conference Call to Announce 2012 Financial Guidance
11. Valeant Pharmaceuticals Completes Acquisition of Dermik
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2020)... JOHNSON CITY, Tenn. (PRWEB) , ... August 26, ... ... claiming both commercial and in-home air purification systems kill Coronavirus. While air purification ... spread of viruses including SARS and even Ebola, no air purification system has ...
(Date:8/26/2020)... ... August 26, 2020 , ... Crossroads Hospice & ... CHC and CPCO to her name. , That’s thanks to her completion of ... the Certified Professional Compliance Officer (CPCO.) , The CHC is designed to mitigate ...
(Date:8/26/2020)... ... 26, 2020 , ... NucleusHealth, LLC, a provider of market ... and Chief Executive Officer effective immediately. Dr. Vishal Verma, the previous CEO, will ... , Mr. Hooton, a seasoned business executive, joined the company in February ...
Breaking Medicine Technology:
(Date:8/31/2020)... ... 31, 2020 , ... A Cure for Covid-19 “PTS” with Mediation & Hypnosis , At ... a state of panic, experiencing deep anxiety, immense stress, and right now are needing serious ... when most people on the planet are experiencing a great degree of emotional discomfort, be ...
(Date:8/31/2020)... ... August 31, 2020 , ... Bonde Innovations, LLC, ... with advanced heart failure, today announced that the company has been awarded a ... from the National Heart, Lung, and Blood Institute of the National Institutes of ...
(Date:8/28/2020)... Ariz. (PRWEB) , ... August 28, 2020 , ... ... respiratory assist system designed to help treat patients with respiratory conditions, including COVID-19, ... mixture of helium and oxygen, but it captures exhaled gas and scrubs it ...
(Date:8/28/2020)... ... August 28, 2020 , ... Integrated Viral Protection (IVP Air) ... school to deploy its breakthrough Mobile Biodefense Indoor Air Protection System that is the ... Academy plans to fully reopen equipped with the filtration system on September 8th. ...
(Date:8/27/2020)... ... 27, 2020 , ... Walk-in Dermatology’s SK-IN Medical Aesthetics Center ... New York location. , Loren received her New York esthetic license in ... chemical peels, microdermabrasion, Hydrafacial MD, dermaplaning, facial lymphatic, and various laser procedures. Loren ...
Breaking Medicine News(10 mins):